Vestipitant
(Preusmjereno sa stranice FRBNMOFIMDUNIJ-UHFFFAOYSA-N)
Vestipitant je razvio GlaksoSmitKlajn. Ovaj lek deluje kao selektivni antagonist za NK1 receptor. On je u razvoju kao potencijalni antiemetik i anksiolitik[3][4], i kao lek za tinitus.[5]
| |||
| (IUPAC) ime | |||
|---|---|---|---|
| (2S)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methylpiperazine-1-carboxamide | |||
| Klinički podaci | |||
| Identifikatori | |||
| CAS broj | 334476-64-1 | ||
| ATC kod | nije dodeljen | ||
| PubChem[1][2] | 9832383 | ||
| Hemijski podaci | |||
| Formula | C23H21F10N3O | ||
| Mol. masa | 545.416 g/mol | ||
| SMILES | eMolekuli & PubHem | ||
| |||
| Farmakoinformacioni podaci | |||
| Trudnoća | ? | ||
| Pravni status | |||
Reference uredi
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Reddy, GK; Gralla, RJ; Hesketh, PJ (2006). „Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis”. Supportive cancer therapy 3 (3): 140–2. DOI:10.3816/SCT.2006.n.011. PMID 18632487.
- ↑ Brocco, M; Dekeyne, A; Mannoury La Cour, C; Touzard, M; Girardon, S; Veiga, S; De Nanteuil, G; Dejong, TR i dr.. (2008). „Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents”. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 18 (10): 729–50. DOI:10.1016/j.euroneuro.2008.06.002. PMID 18657401.
- ↑ Clinical Trials NCT00394056 Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss
